Perrigo Co., Allegan, Mich., said it received final FDA approval to manufacture and market Ciclopirox shampoo, 1%, a generic version of Loprox shampoo. Loprox (Ciclopirox shampoo, 1%) is an antifungal indicated for the treatment of seborrheic dermatitis of the scalp in adults. Estimated annual brand sales for the product during the last 12 months were $26 million, according to data from Wolters Kluwer.

“This approval is another example of Perrigo’s commitment to expand our portfolio and bring new products to market,” said Joseph Papa, chairman and CEO of Perrigo. “It further demonstrates our strategy to deliver quality affordable healthcare for generic prescriptions and over-the-counter products.”